On June 1, 2021 Mark A. Sirgo became a member of the Nominating and Corporate Governance Committee of the Board of Directors of BioDelivery Sciences International, Inc. as he became independent under applicable rules of The Nasdaq Stock Market and the U.S. Securities and Exchange Commission. On July 27, 2021, Mark A. Sirgo resigned from the NCG Committee. The Board of Directors values Mr. Sirgo’s extensive experience as a pharmaceutical company executive, his experience in pharmaceutical development and commercialization and the valuable strategic advice he continues to provide to the Company.